BRGSF-HIS: A Translational Model for B Cell-Targeting TCEs in Autoimmunity

• Robust human lymphoid and myeloid reconstitution without GvHD, enabling long-term immunotherapy studies.
• Clinically relevant B-cell depletion and T-cell pharmacodynamics with therapies targeting autoreactive B cells.
• Integrated efficacy and CRS-like safety assessment in a single translational platform.

Speakers:

Kader Thiam

CSO & Senior Vice President

GenOway